Key result
PDE-5 inhibitors may lower pulmonary pressures and improve RV function in Cpc-PH HFpEF.
Why the study?
Pulmonary vasculopathy in HFpEF may be partially reversible, highlighting the need to evaluate pulmonary vascular targeted therapies such as phosphodiesterase inhibitors in PH-HFpEF.
Do phosphodiesterase inhibitors improve outcomes in patients with heart failure with preserved ejection fraction and pulmonary hypertension?
Do phosphodiesterase inhibitors improve outcomes in patients with heart failure with preserved ejection fraction and pulmonary hypertension?
PDE5 inhibitors represent a potentially targeted therapy for the subset of HFpEF patients who develop combined pre- and post-capillary pulmonary hypertension and right ventricular dysfunction.
Pulmonary hypertension (PH) is common in patients with heart failure with preserved ejection fraction (HFpEF). A chronic increase in mean left atrial pressure leads to passive remodeling in pulmonary veins and capillaries and modest PH (isolated postcapillary PH, Ipc-PH) and is not associated with significant right ventricular dysfunction. In approximately 20% of patients with HFpEF, "precapillary" alterations of pulmonary vasculature occur with the development of the combined pre- and post-capillary PH (Cpc-PH), pertaining to a poor prognosis. Current data indicate that pulmonary vasculopathy may be at least partially reversible and thus serves as a therapeutic target in HFpEF. Pulmonary vascular targeted therapies, including phosphodiesterase (PDE) inhibitors, may have a valuable role in the management of patients with PH-HFpEF. In studies of Cpc-PH and HFpEF, PDE type 5 inhibitors were effective in long-term follow-up, decreasing pulmonary artery pressure and improving RV contractility, whereas studies of Ipc-PH did not show any benefit. Randomized trials are essential to elucidate the actual value of PDE inhibition in selected patients with PH-HFpEF, especially in those with invasively confirmed Cpc-PH who are most likely to benefit from such treatment.
No takes yet. Share an insight, caveat, or question.
Овчинников et al. (2022) conducted a review in Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. Phosphodiesterase (PDE) inhibitors was evaluated. Phosphodiesterase type 5 inhibitors may decrease pulmonary artery pressure and improve right ventricular contractility in HFpEF patients with combined pre- and post-capillary pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: